16-Oct-2026 13:09:54
WANBURYExpansion
WANBURY : NEW METFORMIN BUSINESS IN SAUDI ARABIA, MEXICO WORTH RS 25 CR/YR
• Received 9 "No DMF Deficiency" letters from USFDA for Metformin HCl DMF during July-August 2026 • Also received "No DMF Deficiency" letters for two APIs, Paroxetine and Diphenhydramine HCl • Saudi Arabia: commercialised new Metformin DC (directly compressible) business with annual revenue potential of about ₹10 Cr • Mexico: customer won a two-year Metformin supply tender valued at approximately ₹15 Cr per annum • Validating new APIs Quetiapine Fumarate, Sitagliptin and Empagliflozin; regulatory filings planned next quarter for semi-regulated markets • USFDA and EU-GMP approved facilities at Tanuku (Andhra Pradesh) and Patalganga (Maharashtra); APIs exported to over 50 countries
Wanbury Limited
Open attachment